Description
Introduction: Every year in the Republic, the number of patients detected for the first time is more than 10% of the total 73,000 registered patients with type 2 diabetes mellitus (T2). Metformin is the first-line drug for starting therapy for the majority of patients. The issues of affordability of Metformin for patients with T2 are relevant.
Objective: To study of affordability of metformin for patients with type 2 diabetes mellitus.
Methods: The economic affordability of T2 treatment was estimated using the methodology developed by WHO and the International Actions in the field of healthcare. An average daily dose of 2000 mg was taken to calculate the economic costs of a monthly course of pharmacotherapy of T2 with metformin.
Results: The average price of metformin in the pharmacy network of the Kyrgyz Republic varies greatly depending on the dosage, number of tablets in the package and manufacturers. The cheapest of 10 trade names of metformin is a one-month course of pharmacotherapy with Metfogamma 850 mg, №120 (USD 2.75). The most expensive course of treatment of patients with Dm2 is obtained when using the trade name of Glucophage with a dose of 500 mg, №30 (USD 18.5). The use of drugs with dosage of 1000 mg and 850 mg with packing №120 and №60 tablets is more favorable than the dosage of 500 mg №30.
It was found that a patient with Dm2 spends more than one day's average monthly salary on a monthly course of treatment, i.e. treatment is not economically affordable.
Conclusion:
Despite the availability of a wide range of trade names of Metformin, the issues of affordability remain relevant. Effective reimbursement and price regulation mechanisms need to be developed to ensure the affordability of Metformin.
| Contact Geneva Health Forum | I would like to receive information about the GHF 2024 conference and other GHF activities / Je souhaite recevoir des informations sur la conférence GHF 2024 et d'autres activités du GHF. |
|---|
